Lecture 3 Flashcards

1
Q

Aspirin mechanism of action

A

Acetylates ser530 and irreversibly inactivates COX

Aspirin is an acetylsalicyclate and by donating an acetyl group to COX, a salicyclate is formed (a reversible COX inhibitor, but low conc produced unlikely to have a therapeutic effect)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

How does low dose aspirin inhibit platelet aggregation?

A

Platelets express COX1 and TX synthase (major source of TXA2 for platelet aggregation and vasodilatation)

Endothelial cells produce PGI2 (inhibits platelet aggregation)

Acetylated COX can be replaced in endothelial cells but not in platelets therefore TXA2 production is switched off for the platelet lifetime (10 days)

PPIs may also be co-prescribed to limit GI risk

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Actions of aspirin on COX2

A

Aspirin is weakly selective on COX1 but also inhibits COX2

  • Prevents production of PG and TX intermediates
  • Production of 15R-HETE (isomer of 15S-HETE)
  • 15R-HETE converted by 5-LO to produce aspirin triggered lipoxin (ATL)
  • Similar functions to LXA4 e.g. reduced neutrophil chemotaxis/degranulation

Also antagonises CysLT1 receptors (anti-inflammatory)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Side effects of NSAIDs

A
  1. GI BLEEDING: PGs inhibit gastric acid secretion and increase the release of protective mucin
  2. RENAL INSUFFICIENCY & NEPHROPATHY: PGE2/PGI2 play a vasodilatory role in renal blood flow
  3. STROKE/MI: COX2 is constitutively expressed on endothelial/vascular smooth muscle cells. COX inhibition reduces PGI2 synthesis and therefore there is less inhibition of vasodilatation and platelet aggregation
  4. BRONCHOSPASM: mechanism unclear, appears to be COX-dependent
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Side effects specific to aspirin

A

1) REYE’S SYNDROME
Almost exclusively in children. Hepatic encephalopathy, often occurs when taking aspirin for viral symptoms

2) SALICYCLISM
Result of an overdose, often seen in children or following suicide attempts.
-Krebs cycle inhibition and uncoupling of ox-phos, esp in skeletal muscle
-inc O2consumption, inc CO2 production
-chemoreceptor stimulation
-inc ventilation
-respiratory alkalosis (renal HCO3- secretion)
-direct inhibition of resp centres, CO2 accumulation and resp acidosis
-Fever, vomiting, dehydration, resp depression, coma and death

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Treatment of salicyclism

A
  • fluids and HCO3- administered to enhance aspirin elimination
  • activated charcoal absorbs aspirin in the GI tract
  • in severe cases haemodialysis
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Paracetamol mechanism of action

A

poor anti-inflammatory but good anti-pyretic (fever) and analgesic properties

Inhibits both COX 1 and 2 with some COX2 selectivity

Reduces the active site in COX enzymes required for the conversion of PGG2 to PGH2

In canines paracetamol inhibits COX3. Likely non-functional in humans due to shift in reading frame producing a truncated form of COX3

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

What is another name for paracetamol and what is it derived from

A

Acetoaminophen derived from N-acetyl-para-aminophenol

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Mechanism of paracetamol toxicity

A

Paracetamol is eliminated by conjugation, usually conjugated to glutathione

When hepatic conjugation enzymes are saturated oxidases act to metabolise paracetamol to N-acetyl- P -benoquinonimine (NAPQ1)

In OD there is insufficient glutathione and NAPQ1 can oxidise the thiol groups of cellular proteins leading to major hepato and renal toxicity

(NB NAPQ1 is also formed in therapeutic doses suggesting that there are other pathways for its formation)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Symptoms, treatment and risk factors of paracetamol toxicity

A

Symptoms often not observable until 24-48 hours post ingestion

  • nausea, vomiting and liver failure induced death
  • ACETYLCYSTEINE given to increase hepatic glutathione
  • for a 65kg adult toxicity begins at 9.75g
  • alcohol increases risk of toxicity due to upregulation of CYP2E1 which converts paracetamol to NAPQ1
  • fasting also increases the risk as it reduces hepatic glutathione levels
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Serotonin - actions on vasculature

A

Platelets contain 5-HT which is released during platelet activation and aggregation to induce further aggregation. Also causes vasoconstriction in damaged blood vessels

NB can cause both vasodilatation and constriction depending on receptor expression

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Serotonin synthesis and uptake

A

5-HT = 5 hydroxytryptamine

synthesis from tryptophan through tryptophan hydroxylase (Tph) to form 5-hydroxytryptophan and L-aromatic acid decarboxylase (DDC) conversion to 5-hydroxytryptamine

rate limiting step = Tph step

  • Tph1 predominantly in EC cells
  • Tph2 predominantly in neurones

Platelets are not thought to synthesis their own 5-HT. Express a serotonin transporter (SERT) which enables platelets to become loaded with 5-HT when they pass through the intestinal circulation

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Serotonin degradation

A
  1. oxidative deamination via monoamine oxidase
  2. oxidation to produce 5-hydroxyindoleacetic acid (5-HIAA) which is excreted in the urine

urine 5-HIAA levels are an index of systemic 5-HT synthesis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Serotonin receptors

A
  • 5-HT 1A,B,D,F = Gi coupled GPCRs
  • 5-HT 2A-C = Gq coupled
  • 5-HT3 = ionotropic/ligand gated
  • 5-HT4 = Gs coupled
  • 5-HT5A Gi coupled
  • 5-HT6 Gs coupled
  • 5-HT7 Gs coupled
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Emesis

A

Emesis = vomiting

response to chemicals in the intestine or blood or disturbances to the aural labyrinth

2 key components: vomiting centre and chemoreceptor trigger zone (CTZ) - both located in the medulla

Circulating chemicals can activated the CTZ which sends signals to the vomiting centre to produce emesis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Anti-emesis drug targeting 5-HT

A

ONDANSTERON

Visceral afferents to the CTZ and the CTZ itself possess 5-HT receptors. Inhibition of these receptors can prevent vomiting

Commonly used with anti-cancer drugs which induce vomiting by action on serotonin receptors

17
Q

Anti-emesis drug targeting H1

A

CYCLIZINE = H1 receptor antagonist used for motion sickness and other forms of emesis

PROMETHAZINE = also H1R antagonist used for morning sickness

18
Q

Anti-emesis drug targeting muscarinic receptors

A

SCOPOLAMINE

non-selective muscarinic receptor antagonist
action against M1R prevents emesis - used in motion sickness

19
Q

Anti-emesis drug targeting dopamine receptors

A

D2 antagonists DOMPERIDONE & METOCLOPROMIDE

Act predominantly at CTZ but also at receptors in the GI tract

  • metoclopramide can cause acute dystonia due to CNS effects
  • replaced by domperidone. more peripherally selective therefore less dystonia
20
Q

Receptors targeted by anti emetic drugs

A

5-HT
H1
Muscarinic
D2

21
Q

3 hypotheses for the causes of migraine

A
  1. vascular hypothesis
  2. Brain hypothesis
  3. Inflammation hypothesis
22
Q

Vascular hypothesis for migraine

A

Intracerebral vasoconstriction leads to aura and subsequent vasodilatation causes headache

However recent studies have shown that although blood flow changes happen in migraine, headache begins at vasoconstriction and not all substances causing changes in cerebral blood flow induce headache

23
Q

Brain hypothesis for migraine

A

Cortical spreading depression (CSD) spreads across the brain (2-5mm/min)

  • associated with aura
  • CSD = near complete depolarisation which silences neuronal activity for minutes
  • triggered by increased extracellular K+ (with neuronal activity)
  • ionic imbalance and release of H+, glutamate, NO, 5-HT and arachidonic acid
24
Q

Inflammation hypothesis for migraine

A

Activation of trigeminal nociceptors that innervate the meninges and extracranial blood vessels = initial event in migraine resulting in pain and neurogenic inflammation via CGRP release

(brain does not contain nociceptors)

25
Q

Why are the brain and inflammation hypothesis for migraine not mutually exclusive?

A

CSD=quiet EEG. Inc K+ and neuronal depol

Release of NO, 5-HT, AA etc = blood vessel nociceptor activation

Upregulation of matrix metalloprotease (MMP) = BBB disruption = meningeal nociceptor activation

Release of CGRP, SP and neurokinin A which further drive inflammatory pain

Enhanced by activation of a parasympathetic reflex involving activation of the superior salivatory nucleus (SSN) and the sphenopalatine ganglion (SPG) leading to the release of VIP, NO and ACh

26
Q

Role of 5-HT in migraine

A

5-HT clearly implicated in migraine

  • inc urinary 5-HIAA in migraine
  • inc blood 5-HT

Drugs targeting 5-HT function are often efficacious

27
Q

Drugs targeting 5-HT in acute migraine treatment

A

SUMATRIPTAN = 5-HT 1B/D/F agonist

  • 5-HT 1B = vasoconstriction
  • 5-HT 1D/F = nociceptor inhibition
  • peripheral vasoconstriction is unwanted so sumatriptan not advised for patients with coronary heart disease
  • Via oral administration poorly abs and does not cross BBB to a great extent. Also available as nasal spray or sc injection

LASMITIDAN = 5-HT 1F agonist (may be more useful that 1D)

NARATRIPTAN: longer duration of action, can cross BBB and fewer cardiac effects

28
Q

British Association for the study of headache recommendation for acute migraine therapy

A

Treatment ladder

  • begins with NSAIDs sometimes with an antiemetic e.g domperidone
  • then move to triptans

painkiller use should be limited (2/3 days per week) to prevent overuse and enable treatments to work

29
Q

Migraine prophylaxis drugs

A

Propranolol

Amitryptiline

Topiramate

Botulinum toxin A

30
Q

propranolol in migraine prophylaxis

A

Thought to stop extracerebral vasodilatation by acting on CNS catecholaminergic system

(should be avoided in asthmatics)

31
Q

Amitrypiline in migraine prophylaxis

A

Antidepressant used in lower doses to prevent migraine

MoDA unclear but thought to involve NaV and NET/SERT

32
Q

Topirimate in migraine prophylaxis

A

Anti-epileptic originally

Blocks Nav, faciliatates GABAa - tingling in hand and feet

33
Q

Botulinum toxin A in migraine prophylaxis

A

Only for chronic migraine (>15 days/month)

i.m injection to head and neck
MODA unclear but may work via reduced nociceptor transmitter release

34
Q

Erenumab

A

anti-CGRP receptor mAB

CGRP implicated in migraine. Increased conc in jugular vein during attacks and CGRP infusion induces migraine like attacks in migraineurs but not in non-migraineurs

35
Q

Familial hemiplegic migraine

A

FHM = migraine and half body paralysis

due to mutations in various genes e.g. CACNA1C which encodes CaV1.2

  • may reduce threshold for CSD initiation
  • no RCTs but CaV inhibitors appear efficacious in acute attacks and prophylaxis
36
Q

TRESK

A

2 pore domain K+ channel
Plays a role in regulating resting membrane potential
TRESK expressed by nociceptors

Some dominant negative mutations associated with migraine

Lowered TRESK may predispose to migraine attacks. TRESK agonists are a potential therapy